SGMO
Sangamo Therapeutics Inc

14,354
Mkt Cap
$122.45M
Volume
26,075.00
52W High
$1.40
52W Low
$0.3552
PE Ratio
-1.16
SGMO Fundamentals
Price
$0.513
Prev Close
$0.3639
Open
$0.411
50D MA
$0.4359
Beta
1.72
Avg. Volume
5.65M
EPS (Annual)
-$0.4856
P/B
26.46
Rev/Employee
$315,846.99
Loading...
Loading...
News
all
press releases
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Receives Average Recommendation of "Hold" from Brokerages
Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Get Free Report) has been given a consensus recommendation of "Hold" by the seven ratings firms that are presently covering the firm, MarketBeat Ratings...
MarketBeat·2mo ago
News Placeholder
More News
News Placeholder
Sangamo Therapeutics (NASDAQ:SGMO) Downgraded to Strong Sell Rating by Wall Street Zen
Wall Street Zen cut shares of Sangamo Therapeutics from a "hold" rating to a "strong sell" rating in a research report on Saturday...
MarketBeat·3mo ago
News Placeholder
Research Analysts Offer Predictions for SGMO FY2025 Earnings
Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Free Report) - HC Wainwright decreased their FY2025 earnings per share estimates for Sangamo Therapeutics in a report released on Monday, November 10th. HC...
MarketBeat·3mo ago
News Placeholder
Q4 Earnings Forecast for SGMO Issued By HC Wainwright
Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Free Report) - HC Wainwright issued their Q4 2025 earnings estimates for shares of Sangamo Therapeutics in a note issued to investors on Monday, November...
MarketBeat·3mo ago
News Placeholder
Sangamo Therapeutics (NASDAQ:SGMO) Releases Quarterly Earnings Results, Misses Expectations By $0.08 EPS
Sangamo Therapeutics (NASDAQ:SGMO - Get Free Report) released its quarterly earnings data on Thursday. The biopharmaceutical company reported ($0.11) EPS for the quarter, missing analysts' consensus...
MarketBeat·3mo ago
News Placeholder
Sangamo Therapeutics (SGMO) Reports Q3 Loss, Lags Revenue Estimates
Sangamo (SGMO) delivered earnings and revenue surprises of -266.67% and -98.84%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
What Makes Sangamo (SGMO) a New Buy Stock
Sangamo (SGMO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks·6mo ago
News Placeholder
Sangamo Therapeutics (SGMO) Reports Q2 Loss, Lags Revenue Estimates
Sangamo (SGMO) delivered earnings and revenue surprises of -14.29% and -9.38%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·6mo ago
News Placeholder
Vanda Pharmaceuticals (VNDA) Reports Q2 Loss, Misses Revenue Estimates
Vanda (VNDA) delivered earnings and revenue surprises of -35.29% and -4.38%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·6mo ago
News Placeholder
Sangamo Therapeutics (SGMO) Reports Q1 Loss, Misses Revenue Estimates
Zacks·9mo ago
<
1
2
...
>

Latest SGMO News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.